Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.84
INCY's Cash to Debt is ranked lower than
81% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. INCY: 0.84 )
Ranked among companies with meaningful Cash to Debt only.
INCY' s 10-Year Cash to Debt Range
Min: 0.35  Med: 1.28 Max: No Debt
Current: 0.84
Equity to Asset -0.05
INCY's Equity to Asset is ranked lower than
93% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INCY: -0.05 )
Ranked among companies with meaningful Equity to Asset only.
INCY' s 10-Year Equity to Asset Range
Min: -1.83  Med: 0.08 Max: 0.82
Current: -0.05
-1.83
0.82
F-Score: 4
Z-Score: 11.35
M-Score: -2.19
WACC vs ROIC
2.15%
48.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.93
INCY's Operating margin (%) is ranked higher than
71% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. INCY: 1.93 )
Ranked among companies with meaningful Operating margin (%) only.
INCY' s 10-Year Operating margin (%) Range
Min: -4064.53  Med: -60.79 Max: 9.05
Current: 1.93
-4064.53
9.05
Net-margin (%) -5.66
INCY's Net-margin (%) is ranked higher than
63% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. INCY: -5.66 )
Ranked among companies with meaningful Net-margin (%) only.
INCY' s 10-Year Net-margin (%) Range
Min: -4565.45  Med: -82.36 Max: 7.67
Current: -5.66
-4565.45
7.67
ROA (%) -4.30
INCY's ROA (%) is ranked higher than
69% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. INCY: -4.30 )
Ranked among companies with meaningful ROA (%) only.
INCY' s 10-Year ROA (%) Range
Min: -70.43  Med: -20.38 Max: 5.19
Current: -4.3
-70.43
5.19
ROC (Joel Greenblatt) (%) 22.87
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. INCY: 22.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4727.38  Med: -137.90 Max: 38.66
Current: 22.87
-4727.38
38.66
Revenue Growth (3Y)(%) 59.60
INCY's Revenue Growth (3Y)(%) is ranked higher than
93% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. INCY: 59.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INCY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.4  Med: 19.50 Max: 194.1
Current: 59.6
-61.4
194.1
EPS Growth (3Y)(%) -42.00
INCY's EPS Growth (3Y)(%) is ranked lower than
87% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. INCY: -42.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.1  Med: -8.70 Max: 64.9
Current: -42
-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

INCY Guru Trades in Q3 2014

Jim Simons 97,916 sh (New)
Mariko Gordon 25,283 sh (+6.55%)
Vanguard Health Care Fund 10,174,343 sh (+6.08%)
Mariko Gordon 16,500 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 7,545 sh (-38.28%)
» More
Q4 2014

INCY Guru Trades in Q4 2014

Jim Simons 244,800 sh (+150.01%)
Ken Fisher 14,870 sh (+97.08%)
Vanguard Health Care Fund 10,174,343 sh (unchged)
Mariko Gordon Sold Out
» More
Q1 2015

INCY Guru Trades in Q1 2015

Vanguard Health Care Fund 10,174,343 sh (unchged)
Ken Fisher 14,870 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

INCY Guru Trades in Q2 2015

Ken Fisher 13,695 sh (-7.90%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 88.50
INCY's Forward P/E is ranked lower than
88% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. INCY: 88.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/S 30.74
INCY's P/S is ranked lower than
73% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. INCY: 30.74 )
Ranked among companies with meaningful P/S only.
INCY' s 10-Year P/S Range
Min: 7.19  Med: 23.77 Max: 209.75
Current: 30.74
7.19
209.75
PFCF 780.13
INCY's PFCF is ranked lower than
97% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. INCY: 780.13 )
Ranked among companies with meaningful PFCF only.
INCY' s 10-Year PFCF Range
Min: 7.24  Med: 18.86 Max: 941.29
Current: 780.13
7.24
941.29
POCF 349.71
INCY's POCF is ranked lower than
94% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. INCY: 349.71 )
Ranked among companies with meaningful POCF only.
INCY' s 10-Year POCF Range
Min: 7.19  Med: 19.94 Max: 732.11
Current: 349.71
7.19
732.11
EV-to-EBIT 1183.10
INCY's EV-to-EBIT is ranked lower than
99% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. INCY: 1183.10 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s 10-Year EV-to-EBIT Range
Min: -3055.7  Med: -6.10 Max: 3083.6
Current: 1183.1
-3055.7
3083.6
Current Ratio 3.07
INCY's Current Ratio is ranked lower than
62% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. INCY: 3.07 )
Ranked among companies with meaningful Current Ratio only.
INCY' s 10-Year Current Ratio Range
Min: 1.51  Med: 4.08 Max: 21.14
Current: 3.07
1.51
21.14
Quick Ratio 3.06
INCY's Quick Ratio is ranked lower than
59% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. INCY: 3.06 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s 10-Year Quick Ratio Range
Min: 1.51  Med: 4.08 Max: 21.14
Current: 3.06
1.51
21.14
Days Inventory 47.62
INCY's Days Inventory is ranked higher than
78% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. INCY: 47.62 )
Ranked among companies with meaningful Days Inventory only.
INCY' s 10-Year Days Inventory Range
Min: 46.41  Med: 198.14 Max: 323.15
Current: 47.62
46.41
323.15
Days Sales Outstanding 43.73
INCY's Days Sales Outstanding is ranked higher than
68% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. INCY: 43.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s 10-Year Days Sales Outstanding Range
Min: 12.25  Med: 50.81 Max: 6447.52
Current: 43.73
12.25
6447.52

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.33
INCY's Price/Median PS Value is ranked lower than
57% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. INCY: 1.33 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 0.67 Max: 7.11
Current: 1.33
0.1
7.11
Earnings Yield (Greenblatt) (%) 0.10
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. INCY: 0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 0.80 Max: 1.3
Current: 0.1
0.1
1.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Other Websites
What Will Gilead Buy Next? 4 Possible Targets Jul 15 2015
Celgene Hits High As Street Applauds Receptos Buyout Jul 15 2015
Alexion, Incyte Stage Breakouts Jul 14 2015
Incyte to Report Second Quarter Financial Results on August 4 Jul 14 2015
Incyte to Report Second Quarter Financial Results on August 4 Jul 14 2015
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance Jul 07 2015
Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance Jul 07 2015
Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With... Jun 25 2015
Charting a sluggish, but bullish, summer trend Jun 23 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jun 19 2015
Incyte Announces Organizational and Management Changes to Drive Future Global Expansion Jun 19 2015
Incyte Announces Organizational and Management Changes to Drive Future Global Expansion Jun 19 2015
GEVA helped advance Sectoral Asset 9.4% in May. ALXN did not Jun 17 2015
S&P 500 holds major support, preserving the bull trend Jun 16 2015
JMP Sees A 'Negative Market Tone' In Biotechnology Jun 15 2015
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Jun 10 2015
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Jun 10 2015
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Jun 10 2015
The S&P 500 has reached a critical technical test Jun 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK